ImmunityBio launched the ResQ215B Phase 2 trial of a chemotherapy free, outpatient immunotherapy regimen for indolent B cell non Hodgkin lymphoma. The trial combines CAR NK cell therapy with the ...
SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor ...
SHANGHAI & SUZHOU, China, October 30, 2025--(BUSINESS WIRE)--Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe ...
The use of the IL-15RAFC superagonist N-803 with intravesical bacillus Calmette-Guérin (BCG) resulted in high and more durable response rates in patients with non-muscle invasive bladder cancer (NMIBC ...
Please provide your email address to receive an email when new articles are posted on . A clinical-stage biopharmaceutical company has announced positive topline data from a study evaluating a novel, ...
- provides a platform of next generation reproductive products for Bioniche Animal Health - BELLEVILLE, ON and ROCKVILLE, MD, June 23 /PRNewswire-FirstCall ...
SOTIO will present three posters discussing data that highlight the encouraging safety and efficacy for SOT101 (SO-C101) as a monotherapy and in combination with pembrolizumab for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results